Science First – White paper

creos™ xenoprotect:strong native collagen membrane
High mechanical strength1– High suture retention– High tear resistance

Easy handling– Does not stick to instruments or itself– Either side can face the defect– Low surface expansion when hydrated

Facilitates new bone formation2, 3– Significantly higher new bone formation in the central portion of the defect,in comparative in vivo study– Associated with significantly increased expression of growth factor BMP-2​

Schematic showing the defect height:

High success rate proven in
randomized controlled trial4
In an RCT published by Dr. Istvan Urban et al., creos
xenoprotect and Geistlich Bio-Gide® similarly reduced defectheight after simultaneous GBR and implant placement.

High tensile strength and suture retention1
Studied in vitro compared to other collagen membranes– Showed the highest suture retention when hydrated (6.1 N)​– Demonstrated the highest force at break, wet (21.2 N)

Prior to treatment
4.9 ± 1.9 mm

1.0 ± 1.3 mm

1.7 ± 2.1 mm

creos™
xenoprotect

Referencecreos™
xenoprotect

Reference

Comparison of commercial membranes in a hydrated state876543210creos™ CO

Stable during the period requiredfor barrier function5
After 20 weeks in an animal model, the thickness of creos
xenoprotect decreased only slightly, whereas Geistlich
Bio-Gide® showed around a 50% thickness loss.

6 months after GBR

5.1 ± 2.1 mm

JS

OFBGBEMLOPBM

Sutureretention
wet [N]

Non-cross-linked collagen membranes (NXL) – creos
xenoprotect [Nobel Biocare]; CO: Copios [Zimmer]; JS:Jason [botiss]; OF: Osseoguard Flex [3i]; BG: Bio-Gide[Geistlich]
Cross-linked collagen membranes (XL) – BE: BioMend
Extend [Zimmer]; ML: Mem-Lok [BioHorizons]; OP:OssixPlus [Datum Dental]; BM: BioMend [Zimmer];*Statistically significant

Proprietary production processNobel Biocare's German manufacturing site, Matricel, tested
30 processing techniques so that they could produce the productwith the best cell compatibility and mechanical strength.

Manufacturing site of creos xenoprotect

Clinical caseabcdefghijImages courtesy of Dr. B. Wessing, Germany

A 54-year-old male patient reported with missing teeth 30, 31. Poor bone quantity with 2–3 mm thickness at
the crest and 8 mm and 6 mm of residual bone, respectively, on top of the nervus alveolaris inferior region.
(a, b) Preoperative assessment​(c) Cortical perforations and tenting screws applied​(d) creos xenoprotect and bone graft applied​(e) Graft immobilized – spanning of creos xenoprotect(f) Panoramic radiograph after GBR​(g) After 6 months: 3 mm vertical, 8 mm horizontalbone gain(h, i) Immediately after implant placement ​(j) Situation after four months’ healing

Dr. Fabrizio Colombo ​Oral surgeon, Italy

Dr. Andrew Peterson
Periodontist, USADr. Catherine Rivière
Periodontist, France“Strength and elasticity of creos
xenoprotect can protect andstabilize the grafted area even in
the most challenging cases.”“Utilizing creos xenoprotect andcreos allo.gain in your GBR cases
results in a synergistic interaction
for a predictable outcome.”“I use creos xenoprotect combinedwith creos xenogain particularly
in cases of GBR. The membrane,
stabilized by pins, offers significantstrength and stability.”More to explore

Scientificevidence

Clinical cases

Production &handling movie

1. Gasser A, et al. J Dent Res 2016,95(Spec Iss A): 1683 • 2. Wessing B, et al. Clin Oral Impl Res; 2017;28(11):e218-e226 • 3. Omar O,et al. Clin Oral Impl Res; 2018;29(1):7-19 • 4. Urban I, et al. Clin Oral Impl Res. 2019;30:487–497 • 5. Bozkurt A, et al. Clin Oral Impl Res;
2014;25(12):1403-1411. ​89070 A NA 2312 (Rev 00, 12/23) Printed in USA © Nobel Biocare USA, LLC, 2023. All rights reserved. Distributed by: Nobel Biocare.
Disclaimer: Nobel Biocare, the Nobel Biocare logotype and all other trademarks are, if nothing else is stated or is evident from thecontext in a certain case, trademarks of Nobel Biocare. Please refer to nobelbiocare.com/trademarks for more information. Productimages are not necessarily to scale. All product images are for illustration purposes only and may not be an exact representation ofthe product. Some products may not be regulatory cleared/released for sale in all markets. Please contact the local Nobel Biocaresales office for current product assortment and availability. Caution: Federal (United States) law or the law in your jurisdiction may
restrict this device to sale by or on the order of a dentist or a physician. See Instructions For Use for full prescribing information,
including indications, contraindications, warnings and precautions. creos™ xenoprotect is manufactured by Matricel GmbH,
Kaiserstrasse 100, 52134 Herzogenrath, Germany and distributed by Nobel Biocare. creos™ xenogain is manufactured by Nibec Co.
Ltd., Chungcheongbuk-do, 27816 Korea and distributed by Nobel Biocare.

Why creos
xenoprotect?